Sergey Budagaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergey Budagaev has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Afanasyev
Meshalkin National Medical Research Center Novosibirsk Russian Federation
4 shared publications - Alexander Vladimirovich Bogachev-Prokophiev
Meshalkin National Medical Research Center
4 shared publications - A. S. Zalesov
Meshalkin National Medical Research Center
3 shared publications - Ravil M. Sharifulin
Meshalkin National Medical Research Center
3 shared publications - Михаил Александрович Овчаров
Meshalkin National Medical Research Center
3 shared publications - Andrey V. Sapegin
Meshalkin National Medical Research Center
2 shared publications
Latest Publications
- Open Access
- 13 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (4) , 540-547
Results of concomitant cryoablation for atrial fibrillation during mitral valve surgery
Concomitant atrial fibrillation ablation during mitral valve (MV) surgery using radio frequency energy sources has been reported previously with excellent outcomes. However, data regarding the effectiveness of concomitant cryoablation remain limited. This study aimed to assess the efficacy of concomitant cryoablation in patients scheduled for MV surgery. Between 2012 and 2020, 242 adult patients who underwent MV surgery and concomitant cryoablation were included. Data on rhythm, medication status and clinical events were assessed at 3, 6 and 12 months, then annually thereafter. Early mortality was 0.4%. The mean follow-up period duration was 43.9 months. The survival rates at 1, 3 and 5 years were 97.3%, 94.3% and 87.7%, respectively. The rates of freedom from atrial arrhythmia paroxysms at 1, 3 and 5 years were 79.0%, 64.0% and 60.5%, respectively. Atrial arrhythmia recurrence was associated with isolated left atrial lesion set (P = 0.038), large right atrial size (P = 0.002), lower surgeon experience (P = 0.003) and atrial fibrillation paroxysms in the early postoperative period (P = 0.002). Concomitant cryoablation during MV surgery is a safe and reproducible technique. The procedure provides acceptable freedom from atrial arrhythmias recurrences during long-term follow-up. The biatrial lesion set has advantages over the left atrium pattern in terms of atrial arrhythmias freedom. Surgeon experience significantly influences atrial fibrillation ablation success. Randomized trials are needed to compare radiofrequency and cryoablation.
- 13 November 2021
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 34 (4) , 540-547
Open AccessResults of concomitant cryoablation for atrial fibrillation during mitral valve surgery
Concomitant atrial fibrillation ablation during mitral valve (MV) surgery using radio frequency energy sources has been reported previously with excellent outcomes. However, data regarding the effectiveness of concomitant cryoablation remain limited. This study aimed to assess the efficacy of concomitant cryoablation in patients scheduled for MV surgery. Between 2012 and 2020, 242 adult patients who underwent MV surgery and concomitant cryoablation were included. Data on rhythm, medication status and clinical events were assessed at 3, 6 and 12 months, then annually thereafter. Early mortality was 0.4%. The mean follow-up period duration was 43.9 months. The survival rates at 1, 3 and 5 years were 97.3%, 94.3% and 87.7%, respectively. The rates of freedom from atrial arrhythmia paroxysms at 1, 3 and 5 years were 79.0%, 64.0% and 60.5%, respectively. Atrial arrhythmia recurrence was associated with isolated left atrial lesion set (P = 0.038), large right atrial size (P = 0.002), lower surgeon experience (P = 0.003) and atrial fibrillation paroxysms in the early postoperative period (P = 0.002). Concomitant cryoablation during MV surgery is a safe and reproducible technique. The procedure provides acceptable freedom from atrial arrhythmias recurrences during long-term follow-up. The biatrial lesion set has advantages over the left atrium pattern in terms of atrial arrhythmias freedom. Surgeon experience significantly influences atrial fibrillation ablation success. Randomized trials are needed to compare radiofrequency and cryoablation.
- Open Access
- 28 September 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (3) , 51-60
Short-term outcomes of surgical atrial ablation and septal myectomy
Background. Hypertrophic cardiomyopathy is one of the most common types of cardiomyopathy. The appearance of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy is associated with significant clinical worsening. Outcomes of surgical ablation and septal myectomy in these patients are limited.Aim. This retrospective study aimed to evaluate short-term outcomes of concomitant surgical ablation and septal myectomy in patients with obstructive hypertrophic cardiomyopathy and atrial fibrillation.Methods. Fifty-five patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation who underwent concomitant surgical ablation and septal myectomy between 2014 and 2019 were analysed. Patients with paroxysmal atrial fibrillation predominantly underwent left atrial ablation, and those with nonparoxysmal atrial fibrillation predominantly underwent the Maze IV procedure. Surgical ablation was performed using cryoablation alone (83.6%) or in combination with radiofrequency energy (16.4%).Results. Hospital mortality was 1.8%. Incidence of major adverse events was 3.6%. Sinus node dysfunction and atrioventricular block occurred in 7.3% and 1.8% of patients, respectively. Bleeding requiring revision occurred in 2 (3.6%) patients. Forty-nine (89.1%) patients had stable sinus rhythm and five (9.1%) were on dual-chamber pacemaker stimulation at the time of discharge.Conclusion. Concomitant septal myectomy and surgical ablation are feasible and safe in patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation.Received 5 April 2021. Revised 16 May 2021. Accepted 17 May 2021.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflicts of interests.Contribution of the authorsConception and study design: A.S. Zalesov, A.V. Bogachev-ProkophievData collection and analysis: A.S. Zalesov, S.A. Budagaev, A.V. SapeginStatistical analysis: A.S. Zalesov, A.V. Afanasyev, R.M. SharifulinDrafting the article: A.S. ZalesovCritical revision of the article: A.V. Bogachev-Prokophiev, S.I. Zheleznev, I.I. DeminFinal approval of the version to be published: A.S. Zalesov, A.V. Bogachev-Prokophiev, A.V. Afanasyev, R.M. Sharifulin, A.V. Sapegin, S.A. Budagaev, S.I. Zheleznev, I.I. Demin
- 28 September 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (3) , 51-60
Open AccessShort-term outcomes of surgical atrial ablation and septal myectomy
Background. Hypertrophic cardiomyopathy is one of the most common types of cardiomyopathy. The appearance of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy is associated with significant clinical worsening. Outcomes of surgical ablation and septal myectomy in these patients are limited.Aim. This retrospective study aimed to evaluate short-term outcomes of concomitant surgical ablation and septal myectomy in patients with obstructive hypertrophic cardiomyopathy and atrial fibrillation.Methods. Fifty-five patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation who underwent concomitant surgical ablation and septal myectomy between 2014 and 2019 were analysed. Patients with paroxysmal atrial fibrillation predominantly underwent left atrial ablation, and those with nonparoxysmal atrial fibrillation predominantly underwent the Maze IV procedure. Surgical ablation was performed using cryoablation alone (83.6%) or in combination with radiofrequency energy (16.4%).Results. Hospital mortality was 1.8%. Incidence of major adverse events was 3.6%. Sinus node dysfunction and atrioventricular block occurred in 7.3% and 1.8% of patients, respectively. Bleeding requiring revision occurred in 2 (3.6%) patients. Forty-nine (89.1%) patients had stable sinus rhythm and five (9.1%) were on dual-chamber pacemaker stimulation at the time of discharge.Conclusion. Concomitant septal myectomy and surgical ablation are feasible and safe in patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation.Received 5 April 2021. Revised 16 May 2021. Accepted 17 May 2021.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflicts of interests.Contribution of the authorsConception and study design: A.S. Zalesov, A.V. Bogachev-ProkophievData collection and analysis: A.S. Zalesov, S.A. Budagaev, A.V. SapeginStatistical analysis: A.S. Zalesov, A.V. Afanasyev, R.M. SharifulinDrafting the article: A.S. ZalesovCritical revision of the article: A.V. Bogachev-Prokophiev, S.I. Zheleznev, I.I. DeminFinal approval of the version to be published: A.S. Zalesov, A.V. Bogachev-Prokophiev, A.V. Afanasyev, R.M. Sharifulin, A.V. Sapegin, S.A. Budagaev, S.I. Zheleznev, I.I. Demin
- Open Access
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 19-26
Edge-to-edge mitral valve repair in the surgical treatment of hypertrophic cardiomyopathy
Septal myectomy is the method of choice for treating symptomatic left ventricular outlet obstruction in patients with hypertrophic cardiomyopathy who are resistant to drug therapy. An important role in persistence, residual obstruction, mitral valve abnormalities and anterior systolic mitral valve movement is systolic anterior motion. Several authors have reported the use of edge-to-edge mitral valve repair in addition to septal myectomy in patients with mild septal hypertrophy. We performed a literature review on the surgical treatment of obstructive hypertrophic cardiomyopathy—mitral valve repair using the edge-to-edge technique with septal myectomy. Four retrospective studies and three clinical cases were analysed. The data of patients who underwent mitral valve repair surgery using the edge-to-edge technique with septal myectomy and had satisfactory long-term clinical and hemodynamic results were studied. This treatment technique should be considered in cases of unexpressed hypertrophy when isolated limited myectomy is insufficient to eliminate the left ventricular outlet or when there is a hemodynamically significant mitral insufficiency caused by anterior systolic movement of the mitral valve that increases the need for intervention on interventricular hypertrophy of the associated disease. Septal defect, plastic mitral valve, surgically significant residual mitral regurgitation and high residual left ventricular outflow gradients in long-term follow-up are feasible, safe and effective for anterior systolic mitral valve movement. Received 28 September 2020. Revised 23 March 2021. Accepted 25 March 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. Ovchinnikova, A.N. Pivkin, I.I. DeminDrafting the article: S.A. Budagaev, A.V. AfanasyevCritical revision of the article: A.V. Bogachev-Prokophiev, D.A. AstapovFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, A.N. Pivkin, D.A. Astapov, I.I. Demin
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 19-26
Open AccessEdge-to-edge mitral valve repair in the surgical treatment of hypertrophic cardiomyopathy
Septal myectomy is the method of choice for treating symptomatic left ventricular outlet obstruction in patients with hypertrophic cardiomyopathy who are resistant to drug therapy. An important role in persistence, residual obstruction, mitral valve abnormalities and anterior systolic mitral valve movement is systolic anterior motion. Several authors have reported the use of edge-to-edge mitral valve repair in addition to septal myectomy in patients with mild septal hypertrophy. We performed a literature review on the surgical treatment of obstructive hypertrophic cardiomyopathy—mitral valve repair using the edge-to-edge technique with septal myectomy. Four retrospective studies and three clinical cases were analysed. The data of patients who underwent mitral valve repair surgery using the edge-to-edge technique with septal myectomy and had satisfactory long-term clinical and hemodynamic results were studied. This treatment technique should be considered in cases of unexpressed hypertrophy when isolated limited myectomy is insufficient to eliminate the left ventricular outlet or when there is a hemodynamically significant mitral insufficiency caused by anterior systolic movement of the mitral valve that increases the need for intervention on interventricular hypertrophy of the associated disease. Septal defect, plastic mitral valve, surgically significant residual mitral regurgitation and high residual left ventricular outflow gradients in long-term follow-up are feasible, safe and effective for anterior systolic mitral valve movement. Received 28 September 2020. Revised 23 March 2021. Accepted 25 March 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. Ovchinnikova, A.N. Pivkin, I.I. DeminDrafting the article: S.A. Budagaev, A.V. AfanasyevCritical revision of the article: A.V. Bogachev-Prokophiev, D.A. AstapovFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, A.N. Pivkin, D.A. Astapov, I.I. Demin
- Open Access
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 108-115
The 2020 American Heart Association / American College of Cardiology guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: What is new?
On 22 December 2020, Circulation published the new American College of Cardiology / American Heart Association guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. The most important guidelines were those concerning pharmacological and invasive methods of treating symptomatic patients with obstruction of the left ventricular outlet. Considering the most recent clinical studies, the indications for invasive methods of treatment have expanded to include septal myectomy and alcohol septal ablation. A separate section in the guidelines has been devoted to the management of non-obstructive hypertrophic cardiomyopathy with preserved left ventricular ejection fraction. The recommendations for patients with hypertrophic cardiomyopathy with atrial fibrillation, ventricular arrhythmias and severe heart failure have been revised. Received 26 March 2021. Revised 12 May 2021. Accepted 13 May 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. OvcharovDrafting the article: S.A. Budagaev, A.V. Afanasyev, A.S. ZalesovCritical revision of the article: A.V. Bogachev-ProkophievFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, A.S. Zalesov, M.A. Ovcharov
- 28 June 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (2) , 108-115
Open AccessThe 2020 American Heart Association / American College of Cardiology guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: What is new?
On 22 December 2020, Circulation published the new American College of Cardiology / American Heart Association guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. The most important guidelines were those concerning pharmacological and invasive methods of treating symptomatic patients with obstruction of the left ventricular outlet. Considering the most recent clinical studies, the indications for invasive methods of treatment have expanded to include septal myectomy and alcohol septal ablation. A separate section in the guidelines has been devoted to the management of non-obstructive hypertrophic cardiomyopathy with preserved left ventricular ejection fraction. The recommendations for patients with hypertrophic cardiomyopathy with atrial fibrillation, ventricular arrhythmias and severe heart failure have been revised. Received 26 March 2021. Revised 12 May 2021. Accepted 13 May 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. OvcharovDrafting the article: S.A. Budagaev, A.V. Afanasyev, A.S. ZalesovCritical revision of the article: A.V. Bogachev-ProkophievFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, A.S. Zalesov, M.A. Ovcharov
- Open Access
- 14 September 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (8) , 3847
First experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis
We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.
- 14 September 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (8) , 3847
Open AccessFirst experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis
We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.